Radiofrequency volumetric thermal ablation of fibroids: a prospective, clinical analysis of two years’ outcome from the Halt trial

Richard S Guido¹*, James A Macer², Karen Abbott³, Janice L Falls⁴, Ian B Tilley⁵ and Scott G Chudnoff⁴

Abstract

Background: Although most myomas are asymptomatic, quality of life is compromised for many women with uterine fibroid disease. Twelve-month outcomes from the Halt Trial have been reported in the literature. Here we analyze the clinical success of radiofrequency volumetric thermal ablation (RFVTA) of symptomatic uterine fibroids at two years of follow up.

Methods: Prospective, multicenter, outpatient interventional clinical trial of fibroid treatment by RFVTA in 124 premenopausal women (mean age, 42.4 ± 4.4 years) with symptomatic uterine fibroids and objectively confirmed heavy menstrual bleeding (≥160 to ≤500 mL).

Outcome measures included: subject responses to validated questionnaires, treatment-emergent adverse events, and surgical re-intervention for fibroids at 24 months postprocedure. Continuous and categorical variables were summarized using descriptive statistics and means and percentages. Comparisons between visits were based on t-tests using repeated measures models. P-values < 0.05, adjusted for multiplicity, were statistically significant.

Results: One hundred twelve subjects were followed through 24 months. Change in symptom severity from baseline was –35.7 (95% CI, –40.1 to –31.4; p<.001). Change in health-related quality of life (HRQL) was 40.9 (95% CI, 36.2 to 45.6; p < .001). HRQL subscores also improved significantly from baseline to 24 months in all categories (concern, activities, energy/mood, control, self-consciousness, and sexual function) [p<.001]. Six patients underwent surgical re-intervention for fibroid-related bleeding between 12 and 24 months providing a re-intervention rate of 4.8% (6/124).

Conclusion: Radiofrequency volumetric thermal ablation of myomas significantly reduces symptom severity and improves quality of life with low surgical re-intervention through 24 months of follow up.

Trial registration: ClinicalTrials.gov: NCT00874029

Keywords: Radiofrequency ablation, Ultrasound, Laparoscopic ultrasound, Fibroid, Myoma, Quality of life
The continued analysis of the subjects’ wellbeing beyond the initial study period of 12 months provides a realistic assessment of the medium-term efficacy of the RFVTA treatment. Our objectives were analyses of qualitative clinical outcomes, as evidenced by subject responses to validated questionnaires [6,7], as well as the incidence of device- and/or procedure-related adverse events and surgical re-intervention for fibroid treatment among those subjects followed to 24 months post RFVTA with the Acessa System (Halt Medical, Inc., Brentwood, California USA).

**Materials and methods**

For this prospective, interventional clinical trial [ClinicalTrials.gov Identifier: NCT00874029], in which subjects served as their own controls, we recruited and enrolled premenopausal women with ≤6 treatable fibroids with no single fibroid exceeding 7 cm in any diameter; these parameters were confirmed by transvaginal ultrasound. The subjects’ primary complaint was heavy cyclic menstrual bleeding (≥160 mL to ≤500 mL), which was confirmed by alkaline hematin analysis. For the clinical trial, the U.S. Food and Drug Administration required menstrual blood loss assessment through 12 months of follow up and suggested quality-of-life assessments thereafter. Recruitment started in February 2009 and enrollment of the last patient was in February of 2011. All subjects signed informed consent and the 11 clinical sites in the United States (N = 9) and Latin America (N = 2) [Appendix A] obtained local institutional review board (IRB) or independent ethics committee (IEC) approval of the protocol. The study continues to be conducted in accordance with the general ethical principles outlined in the Declaration of Helsinki and applicable local or international regulations concerning the rights and welfare of human subjects participating in medical research.

Inclusion criteria for enrolled subjects were premenopausal women of at least 25 years of age, with symptomatic uterine fibroids imaged by transvaginal ultrasound and magnetic resonance imaging, having a uterine size of ≤14 weeks as determined by pelvic examination, a total fibroid volume of ≤300 cm³, a minimum of a three-month history of heavy menstrual bleeding within 6 months of enrollment and desiring uterine conservation. Laboratory inclusion criteria were a normal coagulation profile, a normal Papanicolaou test result, and no history of pelvic surgery.

| Enrolled | N = 137 |
|----------|---------|
| Baseline assessed and treated | N = 137 |
| Analysis set | N = 135 |
| Analysis set entering year 2 | N = 124 |
| Outside protocol inclusion/AH parameters | N = 2 |
| No bleeding assessment at 12 months | N = 11 |
| (3 pregnancies, 4 with no 12 month menses, 1 with Hashimotos Disease, 3 lost to follow up or withdrew) |
| No assessment at 24 months | N = 11 |
| (6 re-interventions, 1 Novasure ablation w/o fibroids, 3 lost to follow up or withdrew, 1 pregnancy) |
| 2-Year follow-up questionnaires possible | N = 113 |
| 24-Month questionnaires received | N = 112 |

**Figure 1** Status of study subjects at 24 months post procedure.
last year, and a hemoglobin level of ≥ 10.0 g/dL at the
time of treatment. Exclusion criteria were radiologic evi-
dence by magnetic resonance imaging of adenomyosis,
pedunculated intracavitary or subserosal fibroids (pres-
ence of types I and II submucous fibroids were allowed);
history of pelvic malignancy or cervical dysplasia; prior
treatment or removal of fibroids; and women desiring
future childbearing. Any contraindications to abdominal
surgery or to anesthesia excluded enrollment. The treat-
ment was free for all study participants.

Radiofrequency volumetric thermal ablation was per-
fomed with the Acessa System, which is comprised of a
dual-function radiofrequency generator, a disposable
3.4-mm handpiece with a deployable seven-needle elec-
trode array and controls for inputting data and modi-
fying generator parameters; two disposable dispersive
electrode pads, which were placed on each thigh; ex-
tension cables; and a foot pedal. A 10-mm or 12-mm
laparoscope was inserted through a 10- or 12-mm um-
bilical trocar, and laparoscopic ultrasound through a
separate 10- or 12-mm trocar (Aloka, Wallingford, CT
USA; BK Medical, Peabody, MA USA) permitted map-
ing of the uterus and identification of the location, size,
and number of all fibroids. The handpiece was inserted
percutaneously (without a trocar) and into the fibroid
using ultrasound guidance and the ablation procedure
was carried out. Details of the procedure and technology
have been presented elsewhere [4,8]. Patients were dis-
charged on the day of treatment after standard postope-
rate care with instructions to return to work and to
normal activities as they felt able and to refrain from
sexual activity for 4–6 weeks. Ibuprofen, naproxen or
celecoxib were prescribed for pain on an as-needed
basis. At each of the follow-up visits (3, 6, 12, and 24
months post procedure), subjects provided written res-
ponses to the validated Uterine Fibroid Symptom and
Quality-of-Life questionnaire (UFS-QOL) [6] and respon-
ded assessments positively or negatively. Of the 124 sub-
jects continuing past the 12-month follow up, six sought
surgical re-interventions, one subject became pregnant,
one chose Novasure ablation as diagnostic hysteroscopy
revealed no myomas, and three subjects were lost to fol-
low up or withdrew from the trial. Of the outstanding
113 Uterine Fibroid Symptom and Quality-of-Life ques-
tionnaires, the 11 sites received 112 completed question-
naires. Demographics of those 124 subjects entering the
second year of the study are presented in Table 1.

As shown in Figure 2, patient-reported symptom se-
verity decreased (improved) most readily from baseline
(61.1 ± 18.6) in the first three months of follow up. Symptom severity scores at 3 months (29.1 ± 18.9), 6
months (28.5 ± 19.3), 12 months (26.6 ± 19.0), and 24
months (25.4 ± 20.6) were similar. The change from the
mean baseline value to that at 24 months for the 112

| Variable          | Statistic/Response a | All sites (n = 124) |
|-------------------|----------------------|---------------------|
| Age (years)       | Mean (SD)            | 42.4 (4.4)          |
|                   | Median               | 43                  |
|                   | Range                | 31 – 52             |
| Race              | White or Caucasian   | 58 (46.8%)          |
|                   | Black or African American | 41 (33.1%)        |
|                   | Asian                | 2 (1.6%)            |
|                   | Other b              | 23 (18.5%)          |
| Ethnicity         | Hispanic or Latino   | 56 (45.2%)          |
|                   | Not Hispanic or Latino | 68 (54.8%)       |
| Smoking History   | Current              | 25 (20.2%)          |
|                   | Past                 | 21 (16.9%)          |
|                   | Never                | 78 (62.9%)          |
| Height (cm)       | Mean (SD)            | 162.5 (8.1)         |
|                   | Median               | 162.6               |
|                   | Range                | 137.2 – 180.3       |
| Weight (kg)       | Mean (SD)            | 80.9 (19.4)         |
|                   | Median               | 79.2                |
|                   | Range                | 49.0 – 147.4        |
| BMI               | Mean (SD)            | 30.5 (6.2)          |
|                   | Median               | 29.2                |
|                   | Range                | 19.8 – 47.3         |

a SD Standard deviation.

b Other, Hispanic, hispanic indigenous, or Caribbean.
subjects with baseline and 24-month symptom severity scores was \(-35.7\) (95\% CI, \(-40.1\) to \(-31.4\)).

Health-related quality of life also improved most readily from baseline (37.3 ± 19.1) to 3 months (75.1 ± 22.1). Successive scores were similar to the 3-month value: 6 months (77.8 ± 20.2), 12 months (79.5 ± 20.6), and 24 months (79.3 ± 21.7). The change at 24 months for the 112 subjects with baseline and 24-month HRQL scores was 40.9 (95\% CI, 36.2 to 45.6).

Patient-reported UFS-QOL subscale scores also improved most readily in the first 3 months of follow up (Figure 3). Improvement from baseline to 24 months for each of the subscales is summarized in Table 2. Concern showed the most improvement (Δ 45.6) and sexual function, although statistically improved, showed the least improvement (Δ 29.2) over the study period. These changes were based on those 112 subjects who had both baseline and 24-month scores.

Mean health state scores (EQ-5D) improved from baseline to 3 months and then changed slightly over time from 85.0 to 84.0 (Figure 4). There was a significant improvement in the mean health state score between baseline and 3 months after treatment (p < .001). Measurements at subsequent intervals showed no continued improvement, but remained statistically improved over baseline.

There was one serious adverse event, which occurred between 12 and 24 months and was possibly related to the procedure. One subject became pregnant and delivered a healthy, full-term baby by Cesarean section. However, during the Cesarean section, the subject lost 1400–1500 mL of blood. Approximately 48 hours later, she experienced abdominal pain with additional blood loss and tissue expulsion. Preliminary pathology indicated degenerative fibroid tissue. The patient received 6 units of blood altogether and was discharged from the hospital with oral iron therapy for her anemia.

Six patients (6/124, 4.8\%) underwent surgical re-intervention for fibroid-related bleeding between 12 and 24 months (Table 3): 4 hysterectomies and 2 hysteroscopic myomectomies. Follow-up pathology revealed multiple small fibroids with adenomyosis in four cases (patients 1, 3, 4, and 6), and a possible polyp (patient 5). Pathology studies were not available for Patient 2.

**Discussion**

The subject device (the Acessa System, Halt Medical, Inc., Brentwood, California USA) and the fibroid ablation...
procedure (RFVTA) were developed and refined by Lee and others specifically for fibroids [5,9]. Despite resolution of fibroid symptoms achieved in his early trials using other radiofrequency ablation systems, Lee found the characteristic bending of the needles an obstacle to accurate and dependable fibroid ablation. The current Acessa System and RFVTA procedure showed promise in feasibility studies carried out in Latin America [8,10] and proved effective and safe during the first 12 months of follow up in the FDA-approved prospective interventional clinical trial [4].

This study describes the continued benefits from 12 months [4] through 24 months of follow up; general and disease-specific quality-of-life outcomes are described. The UFS-QOL and EQ-5D scales have been validated and reported as appropriate for use with long-term follow up of patients with symptomatic uterine fibroids [11]. Coyne et al examined the validity, reliability and responsiveness of the UFS-QOL scale among women with symptomatic fibroids through 12 months of follow up after treatment and among controls (premenopausal women without fibroids) [12]. The patients in our study showed significant improvement in their symptom severity and health-related quality of life from baseline to 3 months post treatment. This was sustained over 2 years, accompanied by a low rate of re-intervention (4.8%).

### Table 2 Improvements in UFS-QOL subscale scores from baseline to 24 months

| Subscale              | Baseline | 24 months | Change in score | 95% confidence interval |
|-----------------------|----------|-----------|-----------------|-------------------------|
| Concern               | 24.7 ± 20.7 | 70.8 ± 28.6 | 45.6           | 39.9, 51.3              |
| Activities            | 37.1 ± 24.1 | 81.1 ± 24.2 | 41.9           | 37.5, 48.2              |
| Energy/Mood           | 38.1 ± 21.8 | 79.3 ± 22.9 | 39.6           | 34.6, 44.6              |
| Control               | 45.5 ± 24.9 | 85.8 ± 22.1 | 39.1           | 33.4, 44.9              |
| Self-consciousness    | 38.2 ± 28.3 | 82.1 ± 21.1 | 42.0           | 36.3, 47.7              |
| Sexual function       | 45.5 ± 29.8 | 74.1 ± 29.1 | 29.2           | 22.7, 35.8              |
Table 3 Surgical re-interventions (6/124, 4.8%) between 12 and 24 months post procedure

| Pt | Treated fibroids | Sympt severity | HRQL | Reintervention | Pathology |
|----|-----------------|----------------|------|----------------|-----------|
|    |                 | Baseline 12 mo| Baseline 12 mo |                |           |
| 1  | 6 Subserosal 5.6; 4.4; 1.5; 3.6; 1.9; 3.0 | 53.1 | 28.1 | 46.6 | 89.7 | Hysterectomy at 16.5 months | Multiple myomas ranging from 0.4 to 4.7 cm; focally irregular endo-myometrial junction |
|    | 2 Intramural 4.8; 4.7 |                 |      |            |           |
|    | 1 Subserosal/Intramural 2.7 |                 |      |            |           |
| 2  | 4 Intramural 5.2; 1.1; 1.8 | 68.8 | 28.1 | 10.3 | 82.8 | Hysteroscopic myomectomy by resection at 15 months | No pathology |
| 3  | 3 Subserosal 5.0; 1.3; 1.9 | 78.1 | 43.8 | 20.7 | 51.7 | Hysterectomy at 14 months | Multiple myomas ranging from 0.6 to 3.4 cm; focal adenomyosis |
| 4  | 1 Intramural 2.0 | 62.5 | 28.1 | 10.3 | 60.3 | Supracervical hysterectomy at 23 months | Only morcellated tissue available. Findings: adenomyosis, leiomyomata, proliferative endometrium |
|    | 1 Submucosal 2.0 |                 |      |            |           |
|    | Undefined 1.9 |                 |      |            |           |
| 5  | 5 Intramural 2.7; 2.6; 8.5; 6.7 | 75.0 | 56.3 | 17.2 | 28.4 | Hysteroscopic myomectomy by resection at 16 months | Focal degenerative changes and features suggestive of polyp |
|    | 1 Undefined 3.2 |                 |      |            |           |
| 6  | 1 Intramural 2.0 | 53.1 | 62.5 | 37.1 | 43.1 | Hysterectomy at 23.5 months | Adenomyosis; multiple myomas ranging in size from 0.4 cm to 1.2 cm |
|    | 1 Subserosal 2.0 |                 |      |            |           |

* Information includes the number of each type of treated fibroid and the maximum diameter (cm) of each fibroid.

† Mean transformed symptom severity scores.

‡ Mean transformed health-related quality-of-life scores.
The 3-month outcomes appear to be predictive of long-term (≥ 2 years) results. Some patients, who did not improve at 3 months, showed improvement at later follow-up periods. Continued follow up to 36 months is planned. Researchers of other fibroid treatments have reported similar improvements in symptom severity and quality of life but with re-intervention rates after two-to-three years nearing 26% [10,13,14].

The introduction of new technologies in gynecology has increased women’s options for the treatment of benign gynecologic conditions. These include the use of global endometrial ablation as an alternative to hysterectomies, especially for those women with abnormal bleeding and adenomyosis, and the use of uterine fibroid embolization for the treatment of fibroids. However, it is important to track the outcomes of new procedures to confirm the durability of the treatment.

Conclusions
Radiofrequency volumetric thermal ablation broadly met the needs of the study patients. The low adverse event and re-intervention rates through 24 months are positive outcomes for patient wellbeing and demonstrate that the improvement in symptoms and the increase in the patients’ quality of life are durable for at least a period of 2 years.

Appendix A
The Halt Study Group
Scott G. Chudnoff, MD, MS
Department of Obstetrics & Gynecology and Women’s Health, Montefiore Medical Center, Einstein and Moses Divisions, Albert Einstein College of Medicine, Bronx, NY, USA

Erika Banks, MD
Department of Obstetrics and Gynecology and Women’s Health, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY USA

Micah Harris, MD
Women’s Health Research, Phoenix, AZ, USA

José Gerardo Garza Leal, MD
Hospital Universitario Nuevo Leon, Monterrey, Nuevo Leon, Mexico

Rodolfo Robles Pemueller, MD
Hospital Universitario Esperanza, Universidad Francisco Marroquin, Guatemala City, Guatemala

Karen Abbott, MD
Athena Gynecology Medical Group, Reno, NV, USA

Jay M. Berman, MD
Department of Obstetrics and Gynecology, Division of Gynecology, Wayne State University School of Medicine, Detroit, MI, USA

David J. Levine, MD
St. John’s Mercy Hospital, St. Louis, MO, USA

Donald I. Galen, MD
Reproductive Science Center of the San Francisco Bay Area, San Ramon, CA, USA

James A. Macer, MD
Pasadena Premier Women’s Health, Pasadena, CA, USA

Janice L. Falls, MD
Department of Obstetrics & Gynecology and Women’s Health, Montefiore Medical Center, Einstein and Moses Divisions, Albert Einstein College of Medicine, Bronx, NY, USA

Ian B. Tilley, MD
Department of Clinical Obstetrics and Gynecology, Los Angeles County and University of Southern California Medical Center, Los Angeles, CA, USA

Richard S. Guido, MD
Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Specialties, University of Pittsburgh Medical School, Magee-Women’s Research Institute, Pittsburgh, PA, USA

Abbreviations
RFVTA: Radiofrequency volumetric thermal ablation; HRQL: Health-related quality of life; EQ-SD: EuroQol health state index; IRB: Institutional review board; IEC: Independent ethics committee; CT: Connecticut; MA: Massachusetts; USA: United States of America; UFS-QOL: Uterine fibroid symptom and quality of life.

Competing interests
The authors received financial support from the study sponsor for supplies and use of hospital and administrative services for the study. RSG has been a consultant, assisting in the development of educational materials for the study sponsor. The authors have no other disclosures.

Authors’ contributions
RSG participated in the design of the study as a principal investigator and surgeon, reported data, and helped draft the manuscript. JAM participated as a principal investigator and surgeon, reported data, and reviewed all drafts of the manuscript. KA participated as a principal investigator and surgeon, reported data, and reviewed all drafts of the manuscript. JLF participated as a principal investigator and surgeon, reported data, and reviewed all drafts of the manuscript. IBT participated as a principal investigator and surgeon, reported data, and reviewed all drafts of the manuscript. SGC participated in the design of the study as principal investigator and surgeon, reviewed and critiqued the statistical analyses, reported data, and reviewed all drafts of the manuscript. All authors read and approved the final manuscript.

Authors’ information
All authors are experienced, board-certified, minimally invasive gynecologic surgeons. In addition, SGC has an advanced degree in biostatistics.
Acknowledgments
The authors acknowledge the assistance of Wainwright Medical Communications (Los Gatos, California), an independent consultancy, for research, editorial, and writing support for the development of the manuscript and Innovative Analytics (Kalamazoo, Michigan) for statistical analyses of the study data. The sponsor paid Wainwright Medical Communications and Innovative Analytics for their work.

Author details
1Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Specialties, University of Pittsburgh Medical Center, Magee-Women’s Research Institute, Pittsburgh, PA, USA. 2Department of Obstetrics and Gynecology, Huntington Hospital, Pasadena, CA, USA. 3Athena Gynecology Medical Group, Reno, NV, USA. 4Department of Obstetrics and Gynecology and Women’s Health, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA. 5Department of Clinical Obstetrics and Gynecology, Los Angeles County and University of Southern California Medical Center, Los Angeles, USA.

Received: 17 June 2013 Accepted: 23 July 2013
Published: 13 August 2013

References
1. Lumsden MA, Wallace EM: Clinical presentation of uterine fibroids. Baillieres Clin Obstet Gynaecol 1998, 12(2):177–195.
2. Munro MG: Abnormal uterine bleeding in the reproductive years. Part I: pathogenesis and clinical investigations. J Am Assoc Gynecol Laparoesc 1999, 6(4):391–428.
3. Cohen JM, Gibor Y: Anemia and menstrual blood loss. Obstet Gynecol Surv 1980, 35(10):597–618.
4. Chudnoff SG, Berman JM, Levine DJ, Harris M, Guido RS, Banks E: Outpatient procedure for the treatment and relief of symptomatic myomas. Obstet Gynecol 2013, 121(5):1075–1082.
5. DeLonzor R, Spero RK, Guaou Guaou N, Boyle D, Skyrnarz-Murphy K, Gonzalves SM: Laparoscopic ultrasound-guided radiofrequency volumetric thermal ablation of symptomatic uterine leiomyomas: feasibility study using the Halt 2000 ablation system. J Minim Invasive Gynecol 2011, 18(3):364–371.
6. Lee BB: Laparoscopic radiofrequency ablation of uterine fibroids. J Minim Invasive Gynecol 2009, 16(Suppl):S101.
7. Bongers MY, Mol BW, Dijkhuizen FP, Brölmann HA: Is balloon ablation as effective as endometrial electrosection in the treatment of menorrhagia? J Lapaomendosc Adv Surg Tech A 2000, 10(2):85–92.
8. Spies JB, Coyne K, Guaccu Guaccu N, Boyle D, Smykatz-Murphy K, Goncalves SM: The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata. Obstet Gynecol 2002, 99(2):299–300.
9. Johnson JA, Luo N, Shaw JW, Kind P, Coons SJ: Valuations of EQ-SD health states: are the United States and United Kingdom different? Medical Care 2005, 43(3):221–28.
10. Hehenkamp WJK, Volkers NA, Birnie E, Reekers JA, Ankum WM: Radiofrequency volumetric thermal ablation of symptomatic uterine leiomyomas: are the United States and United Kingdom different? J Am Assoc Gynecol Laparosc 2011, 18(1):73–85.
11. Mara M, Maskova J, Fucikova Z, Kuzel D, Belsan T, Sosna O: Midterm clinical and first reproductive results of a randomized, led trial comparing uterine fibroid embolization and myomectomy. Cardiovasc Intervent Radiol 2008, 31(1):73–85.
12. Robles R, Aguirre VA, Argueta AI, Guerrero MR: Laparoscopic radiofrequency volumetric thermal ablation of uterine myomas with 12 months of follow-up. Int J Gynecol Obstet 2013, 120(1):65–69.
13. Mara M, Maskova J, Fucikova Z, Kuzel D, Belsan T, Sosna O: Midterm clinical and first reproductive results of a randomized, led trial comparing uterine fibroid embolization and myomectomy. Cardiovasc Intervent Radiol 2008, 31(1):73–85.
14. Bongers MY, Mol BW, Dijkhuizen FP, Brölmann HA: Is balloon ablation as effective as endometrial electrosection in the treatment of menorrhagia? J Lapaomendosc Adv Surg Tech A 2000, 10(2):85–92.